安进(AMGN.US)盘初一度涨近3%，报307.37美元。消息面上，安进周三澄清，其试验性减肥药与骨密度变化之间没有联系，第一阶段的研究结果并不表明存在任何骨安全问题，也没有改变我们对MariTide前景的信心。(格隆汇)

海量资讯、精准解读，尽在新浪财经APP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.